Gastrointestinal Malignancies

Nonfiction, Health & Well Being, Medical, Specialties, Oncology
Cover of the book Gastrointestinal Malignancies by Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS, Springer Publishing Company
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS ISBN: 9781935281436
Publisher: Springer Publishing Company Publication: April 6, 2010
Imprint: Demos Medical Language: English
Author: Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS
ISBN: 9781935281436
Publisher: Springer Publishing Company
Publication: April 6, 2010
Imprint: Demos Medical
Language: English

Gastrointestinal Malignancies

Gastrointestinal (GI) cancers are common diseases worldwide. About 400,000 patients are diagnosed with esophageal cancer worldwide each year and nearly 330,000 die for this disease. Roughly 870,000 patients are newly diagnosed each year with gastric cancer and over 600,000 die from the disease each year. And 940,000 new cases of colorectal cancer are diagnosed annually and 490,000 patients die from this disease.

Management options for patients with GI cancer have undergone dramatic changes in the past decade. New cytotoxic agents, novel targeted agents, surgical and ablative options, as well as a new array of supportative medications have shown substantial progress. With the increased number of therapeutic options from which to choose, the clinician is better placed to offer effective therapy. At the same time the clinician is challenged to keep abreast of the rapidly changing treatment landscape and the newly emerging data that is shaping the options for treatment today and in the future.

Gastrointestinal Malignancies provides a comprehensive and in-depth review of this group of malignancies. This volume reviews the current literature, provides critical evaluations of the data, and offers evidence-based recommendations. The editors and authors are leaders in their fields. The chapters update the current screening tools for colon cancers, assessment of predictive markers such as k-Ras and BRAF in the management of colon cancer as well as the state-of-the-art for use of both cytotoxic chemotherapy and the incorporation of newer biological therapies.

About the Series:

Emerging Cancer Therapeutics is an invited review publication providing a through analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence, current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging.

Features of the Emerging Cancer Therapeutics include:

  • Editorial board of nationally recognized experts across the spectrum of Cancer Therapeutics
  • In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer Therapeutics
  • Issues edited by an authority in specific subject area
  • Focuses on major topics in Cancer Therapeutics with in-depth articles covering advancs in clinical and translational research developments as well as clinical applications and experience
  • Emphasizes multidisciplinary approaches to research and practice
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Gastrointestinal Malignancies

Gastrointestinal (GI) cancers are common diseases worldwide. About 400,000 patients are diagnosed with esophageal cancer worldwide each year and nearly 330,000 die for this disease. Roughly 870,000 patients are newly diagnosed each year with gastric cancer and over 600,000 die from the disease each year. And 940,000 new cases of colorectal cancer are diagnosed annually and 490,000 patients die from this disease.

Management options for patients with GI cancer have undergone dramatic changes in the past decade. New cytotoxic agents, novel targeted agents, surgical and ablative options, as well as a new array of supportative medications have shown substantial progress. With the increased number of therapeutic options from which to choose, the clinician is better placed to offer effective therapy. At the same time the clinician is challenged to keep abreast of the rapidly changing treatment landscape and the newly emerging data that is shaping the options for treatment today and in the future.

Gastrointestinal Malignancies provides a comprehensive and in-depth review of this group of malignancies. This volume reviews the current literature, provides critical evaluations of the data, and offers evidence-based recommendations. The editors and authors are leaders in their fields. The chapters update the current screening tools for colon cancers, assessment of predictive markers such as k-Ras and BRAF in the management of colon cancer as well as the state-of-the-art for use of both cytotoxic chemotherapy and the incorporation of newer biological therapies.

About the Series:

Emerging Cancer Therapeutics is an invited review publication providing a through analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence, current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging.

Features of the Emerging Cancer Therapeutics include:

More books from Springer Publishing Company

Cover of the book Developing a Program of Research in Nursing by Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS
Cover of the book Casebook for DSM-5™ by Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS
Cover of the book The Rural Nurse by Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS
Cover of the book Creativity 101, Second Edition by Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS
Cover of the book Teaching in Nursing and Role of the Educator by Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS
Cover of the book Encyclopedia of Nursing Education by Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS
Cover of the book Headache Medicine by Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS
Cover of the book Leadership and Management Skills for Long-Term Care by Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS
Cover of the book Health Care Politics, Policy, and Services, Third Edition by Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS
Cover of the book Eye Movement Desensitization and Reprocessing (EMDR) Therapy Scripted Protocols and Summary Sheets by Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS
Cover of the book Chemistry and Physics for Nurse Anesthesia, Third Edition by Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS
Cover of the book Nursing in the Storm by Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS
Cover of the book The Health Professions Educator by Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS
Cover of the book Partnerships for Health and Human Service Nonprofits by Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS
Cover of the book Hepatitis C Treatment One Step at a Time by Jame Abraham, MD, FACP, M. Wasif Saif, MD, MBBS
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy